Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – Analysts at HC Wainwright raised their Q2 2026 EPS estimates for Bradmer Pharmaceuticals in a note issued to investors on Wednesday, April 29th. HC Wainwright analyst M. Colonnese now anticipates that the company will post earnings of $0.12 per share for the quarter, up from their previous estimate of ($0.04). HC Wainwright also issued estimates for Bradmer Pharmaceuticals’ FY2026 earnings at $0.12 EPS.
Several other equities research analysts also recently commented on the stock. Citigroup upgraded shares of Bradmer Pharmaceuticals to a “hold” rating in a research note on Tuesday, February 24th. ATB Cormark Capital Markets downgraded shares of Bradmer Pharmaceuticals from a “strong-buy” rating to a “moderate buy” rating in a research note on Thursday, February 5th. Three research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy”.
Bradmer Pharmaceuticals Price Performance
See Also
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
